Femara 1mg


  • Model: Femara 1mg
  • 10000 Units in Stock
  • Manufactured by: New Science Pharmaceutical CO.
Add to Cart:

Letrozole, also known as Femara, is an oral non-steroidal aromatase inhibitor used during the treatment of hormonally-responsive breast cancer after surgery. It is commonly used by athletes and bodybuilders before the end or at the end of an anabolic steroid cycle, especially one involving harsh or aromatizable steroids and performance enhancing drugs.

The chemical name of Letrozole is 4,4′-(1H-1,2,4-Triazol-1ylmethylene)dibenzonitrile and its molecular formula is C17H11N5. The anti-estrogen has the molecular weight of 285.31 g/mol at the base. The active ingredient in Femara tablets is Letrozole, a non-steroidal aromatase inhibitor while the list of inactive ingredients in Femara tablets includes colloidal silicon dioxide, ferric oxide, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, maize starch, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, talc, and titanium dioxide.

Uses Of Letrozole

The drug, Letrozole, is approved by the United States Food and Drug Administration (FDA) for treating local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women.

Since 2001, Letrozole is used for ovarian stimulation by fertility doctors across the world as it has lesser side effects than Clomifene (Clomid) and there are fewer chances of multiple gestations with this drug. Use of this drug can be made during the pretreatment for termination of pregnancy, in combination with misoprostol because of its anti-estrogenic actions. The drug may even be used to promote spermatogenesis in male patients suffering from non-obstructive azoospermia and treating endometriosis. It may also be prescribed to women who have experienced menopause as a first treatment of breast cancer that has spread within the breast or to other areas of the body or in women whose breast cancer has worsened while they were taking tamoxifen.

Since Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers, it can be used to prevent the cancer from returning. Femara can delay progression of advanced breast cancer for 9.4 months compared to 6.0 months for tamoxifen in postmenopausal women with locally advanced (stage IIIB) disease, metastatic breast cancer, or recurrences not amenable to treatment with surgery or radiotherapy.

This nonsteroidal competitive inhibitor inhibits the conversion of androgens to estrogens and is as effective as ovariectomy in reducing uterine weight, elevating serum LH, and causing the regression of estrogen-dependent tumors. Letrozole treatment does not lead to an increase in serum FSH and is associated with selectively inhibition of gonadal steroidogenesis but has no significant effect on adrenal mineralocorticoid or glucocorticoid synthesis. It also has the ability of inhibiting the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. Women treated with this drug experience significantly lower serum estrone, estradiol, and estrone sulfate compared to Tamoxifen and such use is not associated with negatively-impacted adrenal corticosteroid synthesis, aldosterone synthesis, or synthesis of thyroid hormones.

This third-generation selective oral aromatase inhibitor is also admired for its ability to stimulate metabolic rate of the body and promoting burning of fat. It is also used for minimizing the levels of LDL (bad) cholesterol and stimulating dramatic enhancements in the levels of growth hormone, cortisol, sex hormone-binding globulin (SHBG), and hepatic production of binding protein. It also leads to enhanced levels of HDL (good) cholesterol and growth and development of sexual characteristics. When used as per medical recommendations, Femara use can also be associated with healthy immune function, healthy cholesterol levels, joint health, cognitive function, and muscle growth while reducing or even eliminating estrogenic side effects such as oily skin, gynecomastia, and fluid retention.

Recommended Dose Of Letrozole

The recommended dose of Letrozole is 2.5 mg once a day for treating patients with breast cancer. Athletes and powerlifters during steroid cycles use Letrozole in dosages of 0.5-1.0 mg every day, with or without meals. It is best to use this drug at around the same time every day.

This product was added to our catalog on Monday 27 January, 2014.

Proviron 25mg | Anastrozole 1mg | HCG 5000IU | Proviron 25mg | Nolvadex 20mg | Halotestin 10mg | Anadrol 50mg | Turinabol 10mg | HCG 5000IU | Anastrozole 1mg | Femara 1mg | Clenbuterol 50mcg | T4 50mcg | T3 50mcg | Proviron 25mg | C-Alice 20mg | V-Agra 100mg | Winstrol 50mg | Dianabol 50mg | Trenbolone A100 | Clomid 50mg | Winstrol 20mg | Dianabol 20mg | Anavar 20mg | Testosterone P100 | Testosterone E250 | Testosterone C200 | Sustanon 325 | Stanozolol 50 | Primobolon D100 | Masteron 100 | Deca Durabolin 300 | Boldenone 200 |